Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis

Behcet's Syndrome, Vascular Type Clinical Trial

Official title:

The Efficacy of Hydroxychloroquine on Behcet's Disease Thrombotic Events Prevention

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04022421
• Other study ID #: 17300279
• Status: Recruiting
• Phase: N/A
• Start date: October 1, 2018
• Est. completion date: October 2019

Study information

• Verified date: July 2019
• Source: Assiut University
• Contact: Alaa Mohamed, Post-doctor
• Phone: +20882413177
• Email: a.a.a.mohamed[@]aun.edu.eg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients diagnosed with Behcet's disease will be randomized to administeration of hydroxychloroquine. Assessment will be done for the patients at baseline and every one month in the first three months and then quarterly for one year.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: October 2019
• Est. primary completion date: August 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients diagnosed with Behcet's disease on any DMARDs

Exclusion Criteria:

• Patients with critical conditions

• Patients with hypersensitivity or adverse drug reactions to hydroxychloroquine.

Related Conditions & MeSH terms

• Behcet Syndrome
• Behcet's Syndrome, Vascular Type

Intervention

Drug:
• Hydroxychloroquine
the drug will be taken by one group of the patients daily at a dose of 400mg

Locations

Country	Name	City	State
Egypt	Assiut University Hospital	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevention of the recurrence of thrombotic events	number of relapses is expected to fall with the longterm use of the drug	6 months- one year